cerus_small_2x-2
header_image_2x new
Webinar 1 geel-1
Webinar 2 groen
Webinar 3 wit

 

How to bring bacterial risk control strategies within financial reach?

Tuesday May 11th | 3:00 – 4:30 pm (Central European Time)

 

time_2x3:00 – 3:10 pm

Introduction
Kathleen Rowe | Sr. Global Health Policy Director | Cerus Global Headquarters

time_2x3:10 – 3:30 pm

Strategies to minimize budget impact and increase cost effectiveness of pathogen inactivation 
Filip De Groof | Marketing Consultant | Cerus Europe BV 

While an initial investment is required to implement pathogen inactivation, multiple options are available to offset costs and reduce net investment. What are the options and how much can they contribute to minimizing the budget impact for a blood center? If we consider budget impact and clinical benefits, what is the cost-effectiveness of pathogen inactivation and how does it compare with other blood safety measures introduced in the last two decades?

time_2x3:30 - 3:55 pm

Case Study I - A blood center perspective
Pathogen reduction of double dose platelet concentrates from pools of eight buffy coats: product quality, safety and economic aspect
Konrad Rosskopf | Dr. | Department of Blood Group Serology and Transfusion Medicine | Medical University and LKH-Univ. Klinikum Graz

The Blood Center in Graz is one of the first centers worldwide to have optimized pathogen reduction for platelet concentrates from both a product quality and economic perspective. Results of almost 3 complete years of pathogen reduction are compared with a historic control of 3 years before implementation. You will receive insights from results of the initial validation study, the revalidation of the process, routine quality control results and aspects which drive the economic impact of pathogen reduction. 

time_2x3:55 – 4:20 pm

Case Study II – A hospital perspective
Economic aspects of introducing pathogen inactivated platelets in the treatment cycle of oncology patients in Germany
Florian Kron | Prof. Dr. | Centrum for integrated Oncology | University Hospital Cologne

Innovative therapies are associated with high-cost treatments and procedures. Especially in the field of oncology, inpatient treatment is the primary cost driver with high-volume resource consumption in medication and drug administration. Thus, cancer centers need to manage oncology cases in terms of cost and reimbursement. We will review a multidimensional evaluation of the ´economic burden` from a cost and reimbursement perspective in severe oncological diseases. Finally, we will discuss financial challenges and future opportunities for cancer centers.

time_2x4:20 – 4:30 pm

Q&A-session
Kathleen Rowe | Sr. Global Health Policy Director | Cerus Global Headquarters

Please make your choice

I would like to register for webinar 3


Register

I cannot participate in webinar 3, but would like to receive access to the recorded webinar

New call-to-action




cerus_reverse_small_2x

Global headquarters

1220 Concord Avenue
Concord, CA US 94520
+1 925.288.6000

European headquarters

Stationsstraat 79-D
3811 MH Amersfoort, Netherlands
+31 (0)33 49 60 600

 

Copyright 2021, CERUS. All rights reserved. MKT-EN 00477-14, v4.0

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage. Follow us on LinkedIn.